Saturday 17 October 2026
Export BWAY’s income statement to Excel — free account
Brainsway Ltd. Sponsored ADR
BWAY Healthcare Medical Devices
Brainsway Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $52.2 million, up 27.3% from fiscal 2024. In the quarter to June 2026, revenue grew 35.4%, EPS grew 40.0% and free cash flow fell 51.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
11.41
0.41
−3.47%
Follow BWAY
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | 4.00 | 2.55 | 3.45 | 0.82 | 0.69 | 2.31 | 3.92 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | 6.20 | 6.27 | 5.88 | 4.59 | 3.68 | 5.49 | 9.90 | |||||
| People | |||||||||||||||
| People | Employees | — | — | 96 | 107 | 100 | 118 | 134 | 106 | 120 | 129 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.17 | 0.22 | 0.22 | 0.25 | 0.20 | 0.30 | 0.34 | 0.40 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | 11 | 11 | 16 | 23 | 22 | 30 | 27 | 32 | 41 | 52 | ||||
| Gross margin, % | 77.27 | 75.16 | 78.11 | 77.80 | 77.07 | 77.75 | 73.77 | 73.86 | 74.56 | 75.42 | |||||
| EBT | (2) | (7) | (6) | (10) | (5) | (6) | (13) | (4) | 3 | 8 | |||||
| EBT margin, % | (21.69) | (64.53) | (38.24) | (42.88) | (23.34) | (21.64) | (47.96) | (12.41) | 8.43 | 14.76 | |||||
| Net income | (2) | 0 | (6) | (10) | (5) | (6) | (13) | (4) | 3 | 8 | |||||
| Depreciation | 1 | 1 | 1 | 3 | 2 | 2 | 2 | 1 | 2 | 2 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 1.52 | 1.41 | 0.99 | 1.13 | 0.98 | 0.95 | 0.82 | 0.96 | 2.41 | 2.75 | ||||
| Earnings | (0.17) | (0.50) | (0.39) | (0.50) | (0.24) | (0.21) | (0.40) | (0.13) | 0.17 | 0.40 | |||||
| Cash flow | (0.33) | (0.46) | (0.23) | (0.35) | (0.06) | 0.03 | (0.30) | 0.04 | 0.61 | 0.92 | |||||
| Capex | 0.00 | 0.00 | (0.12) | (0.16) | (0.11) | (0.07) | 0.06 | (0.07) | (0.22) | (0.12) | |||||
| Free cash flow | (0.33) | (0.46) | (0.35) | (0.51) | (0.17) | (0.04) | (0.24) | (0.03) | 0.38 | 0.80 | |||||
| Book value | 1.42 | 1.62 | 0.42 | 1.18 | 0.87 | 1.84 | 1.38 | 1.25 | 3.67 | 3.85 | |||||
| Shares, m | 7 | 8 | 17 | 21 | 22 | 31 | 33 | 33 | 17 | 19 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 55.53 | 26.42 | ||||
| P/S | 5.35 | 5.35 | 5.35 | 4.33 | 3.84 | 4.04 | 1.38 | 3.77 | 1.95 | 3.46 | |||||
| P/B | 17.80 | 17.80 | 17.80 | 4.13 | 4.31 | 2.09 | 0.83 | 2.88 | 1.29 | 2.47 | |||||
| EV/Sales | 5.08 | 5.08 | 5.08 | 3.51 | 3.19 | 2.21 | (0.27) | 2.40 | 0.33 | 2.19 | |||||
| EV/FCF | (15.32) | (15.32) | (15.32) | (7.68) | (18.01) | (48.34) | 0.94 | (69.17) | 2.06 | 7.54 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (2) | (4) | (4) | (7) | (1) | 1 | (10) | 1 | 10 | 17 | ||||
| Capex | 0 | (1) | (2) | (3) | (2) | (2) | 2 | (2) | (4) | (2) | |||||
| Free cash flow | (2) | (4) | (6) | (11) | (4) | (1) | (8) | (1) | 7 | 15 | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 9 | 12 | 5 | 22 | 17 | 56 | 50 | 46 | 64 | 61 | ||||
| Total debt | — | 3 | 3 | 0 | 1 | 1 | 0 | — | — | — | |||||
| Net debt | (10) | (12) | (6) | (22) | (17) | (57) | (48) | (46) | (70) | (69) | |||||
| Shareholders’ equity | 10 | 13 | 7 | 24 | 20 | 57 | 45 | 42 | 62 | 73 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (10.19) | (73.09) | (29.71) | (33.14) | (14.80) | (11.78) | (19.04) | (6.59) | 3.71 | 7.30 | ||||
| ROIC | 0.00 | 0.00 | (446.40) | (227.85) | (123.09) | 0.00 | 0.00 | 0.00 | 0.00 | 71.48 | |||||
| ROE | (20.80) | (63.48) | (65.85) | (66.26) | (24.56) | (16.79) | (25.99) | (9.65) | 5.62 | 11.18 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
Brainsway Ltd. Sponsored ADR vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TCMD Tactile Systems Technology, Inc. | $527.6M | 20.5× | 22.7× | +8.61% (above 0%: growing) | +142.86% (above 0%: growing) | −86.53% (below 0%: shrinking) | 76.25% | 7.97% | Compare |
| SSII SS Innovations International, Inc. | $517.2M | — (loss-making) | — (loss-making) | +39.39% (above 0%: growing) | n/m | −16.62% (below 0%: shrinking) | 50.94% | (16.29%) | Compare |
| DCTH Delcath Systems, Inc. | $513.9M | 1,408× | — (loss-making) | +20.60% (above 0%: growing) | −12.50% (below 0%: shrinking) | −24.45% (below 0%: shrinking) | 89.75% | 8.22% | Compare |
| MASS 908 Devices Inc. | $491.5M | — (loss-making) | — (loss-making) | +23.31% (above 0%: growing) | n/m | +150.95% (above 0%: growing) | 51.90% | (79.69%) | Compare |
| SGHT Sight Sciences, Inc. | $484.8M | — (loss-making) | — (loss-making) | +19.55% (above 0%: growing) | n/m | +26.71% (above 0%: growing) | 91.39% | (16.62%) | Compare |
| BWAY Brainsway Ltd. Sponsored ADR | $475.8M | 24.8× | — (loss-making) | +35.43% (above 0%: growing) | +40.00% (above 0%: growing) | −51.68% (below 0%: shrinking) | 74.62% | 13.98% | |
| CERS Cerus Corporation | $455.5M | — (loss-making) | — (loss-making) | +5.28% (above 0%: growing) | n/m | −20.90% (below 0%: shrinking) | 55.91% | (2.94%) | Compare |
| NPCE NeuroPace, Inc. | $438.7M | — (loss-making) | — (loss-making) | +17.05% (above 0%: growing) | n/m | −78.70% (below 0%: shrinking) | 82.83% | (22.53%) | Compare |
| SENS Senseonics Holdings, Inc. | $435.2M | — (loss-making) | — (loss-making) | +117.82% (above 0%: growing) | n/m | −223.24% (below 0%: shrinking) | 59.10% | (248.48%) | Compare |
| Median of peers | $488.1M | — | — | +20.07% | — | −22.67% | 67.68% | (16.45%) |
Brainsway Ltd. Sponsored ADR (BWAY) key facts
- Strength: Brainsway Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $52.2 million, up 27.3% from fiscal 2024.
- Brainsway Ltd. Sponsored ADR (BWAY) is a Medical Devices company in the Healthcare sector, traded in the US as an ADR.
- As of October 16, 2026, BWAY traded at $11.41, a market capitalization of $475.8 million.
- Return on equity was 11.2% and debt-to-equity 0.00.
- Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 2.82 (grey zone) for fiscal 2025.